LEO 27847 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Secondary Hyperparathyroidism Patients

Inclusion Criteria: * Patients aged 18 to 75 years (inclusive) at screening. * Patients with body mass index within 18 to 34 kg/m2 (inclusive). * Haemoglobin is stable (≥9 g/dL or 5.6 mmol/L) * Parathyroid hormone (PTH) is ≥200 pg/mL and \<800 pg/mL. * Screening serum albumin is ≥30 g/L. * C-reactive protein \<25 mg/L. Exclusion Criteria: * Adjustment of vitamin D sterols within 14 days before the screening visit and patients for whom adjustment of vitamin D sterols is planned from screening until end of study. * Adjustment of calcium supplements within 14 days before the screening visit and patients for whom adjustment of calcium supplements is planned from screening until end of study. * Adjustment of phosphate binder within 14 days before the screening visit and patients or whom adjustment of phosphate binder is planned from screening until end of study.